Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ISTA expands pipeline in allergy treatments
Under the terms of the agreement, ISTA will pay an upfront payment of $2 million to Tanabe, additional payments based on achievement of development and approval milestones, and
Under the terms of the agreement, ISTA will pay an upfront payment of $2 million to Tanabe, additional payments based on achievement of development and approval milestones, and
The net proceeds to the company of the offering are approximately $73.8 million, after payment of underwriting discounts and commissions, but excluding estimated offering expenses. Goldman, Sachs &
Valortim is a fully human monoclonal antibody generated by Medarex’s UltiMAb technology, which is being co-developed by the two companies. The up to $13.9 million contract supports the
Under the terms of the agreement, NPS has the potential to earn up to $185 million plus royalties. As an upfront payment, NPS will receive from Nycomed $35
ALKS 27 is an inhaled formulation of trospium chloride, a muscarinic receptor antagonist that relaxes smooth muscle tissue and has the potential to improve airflow in patients with
ITMN-191 is a hepatitis C virus protease inhibitor in development by InterMune and its partner, Roche. The study will assess the effect of multiple doses of ITMN-191 given
CRx-102 osteoarthritis multi-center evaluation trial (COMET) is designed to evaluate the efficacy of CRx-102 compared to placebo in subjects with symptomatic knee osteoarthritis. This clinical trial is a
The CARE-MS I trial (comparison of alemtuzumab and Rebif efficacy in multiple sclerosis), a randomized, rater-blinded study, will compare alemtuzumab to Rebif (interferon beta-1a) in patients with relapsing-remitting
The trial of approximately 132 subjects will evaluate the effect of weekly Asentar doses combined with gemcitabine plus or minus daily erlotinib in the initial treatment of advanced
The study is a randomized, crossover study evaluating formulations of insulin nasal spray as compared to NovoLog insulin aspart, an approved, rapid-acting injectable insulin, on post-meal glycemic control.